SOHO State of the Art Updates and Next Questions | Contemporary Role of Autologous Stem Cell Transplantation for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma in the Era of Cellular Therapies

被引:0
作者
Goel, Utkarsh [1 ]
Mian, Agrima [2 ]
Sauter, Craig S. [2 ]
机构
[1] Cleveland Clin, Dept Internal Med, Cleveland, OH USA
[2] Cleveland Clin, Taussig Canc Ctr, Dept Hematol & Med Oncol, Carnegie Ave,CA-60, Cleveland, OH 10201 USA
关键词
Autologous transplantation; CAR T-cell therapy; High dose therapy; Relapsed DLBCL; Relapsed/refractory DLBCL; SINGLE-ARM; LISOCABTAGENE MARALEUCEL; 2ND-LINE THERAPY; OPEN-LABEL; R-ICE; CHEMOTHERAPY; RITUXIMAB; MULTICENTER; DLBCL; RADIOTHERAPY;
D O I
10.1016/j.clml.2024.07.020
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Since the 1990s, the standard of care for the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) had been salvage chemotherapy followed by high-dose chemotherapy and autologous stem cell transplantation (HDTASCT) in patients with a chemotherapy-sensitive remission. However, promising results from the recent TRANSFORM and ZUMA-7 trials evaluating the efficacy of CAR T-cell therapy versus HDT-ASCT for second line relapsed/refractory DLBCL have sought to challenge this standard of care. While these studies have established a new standard for the treatment of early relapsed and primary refractory DLBCL, significant differences in the trial design between these studies and limitations with the timing of randomization during the disease course warrant a thoughtful interpretation of the results. Additionally, the financial burden and logistic challenges of CAR T-cell administration and limited access to these therapies continue to be ongoing issues. Despite the encouraging results from these trials, HDT-ASCT continues to have a role in the treatment of DLBCL, especially in disease relapsing >= 12 months after initial therapy, and in chemo sensitive disease with a good response to salvage chemotherapy. Ongoing studies evaluating novel salvage regimens for use prior to HDT-ASCT, and future studies evaluating the role of CAR T-cell therapy in chemo sensitive disease will help determine the continued role of HDT-ASCT for relapsed/refractory DLBCL.
引用
收藏
页码:219 / 225
页数:7
相关论文
共 50 条
[21]   Targeted Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Tafasitamab in Context [J].
Abdulhaq, Haifaa ;
Hwang, Andrew ;
Mahmood, Omar .
ONCOTARGETS AND THERAPY, 2023, 16 :617-629
[23]   Allogeneic Hematopoietic Stem Cell Transplant for Diffuse Large B-Cell Lymphoma: Evolving Role in the Era of CAR T-Cell Therapy [J].
Hilal, Talal ;
Mountjoy, Luke J. .
CURRENT ONCOLOGY REPORTS, 2023, 25 (06) :599-607
[24]   Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed/Refractory Diffuse Large B Cell Lymphoma [J].
Xiao, Zhengrui ;
Li, Jianyong ;
Miao, Kourong .
CURRENT STEM CELL RESEARCH & THERAPY, 2017, 12 (01) :14-18
[25]   Relapsed or Refractory Diffuse Large B-Cell Lymphoma: "Dazed and Confused" [J].
Kesireddy, Meghana ;
Lunning, Matthew A. .
ONCOLOGY-NEW YORK, 2022, 36 (06) :360-369
[26]   Ofatumumab with iphosphamide, etoposide and cytarabine for patients with transplantation-ineligible relapsed and refractory diffuse large B-cell lymphoma [J].
Paszkiewicz-Kozik, Ewa ;
Michalski, Wojciech ;
Taszner, Michal ;
Mordak-Domagala, Monika ;
Romejko-Jarosinska, Joanna ;
Knopinska-Posluszny, Wanda ;
Najda, Jacek ;
Borawska, Anna ;
Chelstowska, Monika ;
Swierkowska, Monika ;
Dabrowska-Iwanicka, Anna ;
Malenda, Agata ;
Druzd-Sitek, Agnieszka ;
Konecki, Robert ;
Kumiega, Beata ;
Osowiecki, Michal ;
Ostrowska, Beata ;
Szpila, Tomasz ;
Szymanski, Marcin ;
Targonski, Lukasz ;
Domanska-Czyz, Katarzyna ;
Poplawska, Lidia ;
Giebel, Sebastian ;
Lange, Andrzej ;
Pluta, Andrzej ;
Zaucha, Jan Maciej ;
Rymkiewicz, Grzegorz ;
Walewski, Jan .
BRITISH JOURNAL OF HAEMATOLOGY, 2022, 198 (01) :73-81
[27]   Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma: a review of clinical data [J].
Furqan, Fateeha ;
Hamadani, Mehdi .
THERAPEUTIC ADVANCES IN HEMATOLOGY, 2022, 13
[28]   Stem cell transplantation for diffuse large B-cell lymphoma patients in the rituximab era [J].
Mounier, Nicolas ;
Gisselbrecht, Christian .
CURRENT OPINION IN ONCOLOGY, 2011, 23 (02) :209-213
[29]   High-dose rituximab in combination with autologous stem cell transplantation for relapsed or refractory diffuse large B cell lymphoma [J].
Shi, Yi-Fen ;
Zhou, Shu-Juan ;
Sun, Lan ;
Yu, Kang ;
Chen, Yi .
MEDICINA CLINICA, 2020, 155 (06) :235-241
[30]   Loncastuximab tesirine for treatment of relapsed or refractory diffuse large B cell lymphoma [J].
Goparaju, Krishna ;
Caimi, Paolo F. .
EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (11) :1373-1381